In Vivo Synergism Between Chemotherapy and the 3C23K Monoclonal Antibody Targeting the AMH-type II Receptor in Ovarian Cancer PDX Models

Background: Müllerian inhibiting substance, also called anti-Müllerian hormone (AMH), belongs to the TGF-alpha family and plays a key role during sexual development. Various reports have underlined expression of AMHRII in human gynecologic cancers including ovarian cancers (OC). Based on these considerations, a humanized glyco-engineered monoclonal antibody (3C23K) specific to AMHRII has been developed. In this study, we have assessed AMHRII expression in a panel of OC patient-derived xenografts (PDXs) and evaluated in vivo efficacy of 3C23K.